Cough syrup case: Govt recommends cancellation of Marion Biotech's licence

The company Marion Biotech had supplied the cough syrups that reportedly caused the deaths of Children in Uzbekistan

cough syrup, medicine, cold
cough syrup
2 min read Last Updated : Mar 04 2023 | 11:27 PM IST
The Central government on Saturday recommended the Uttar Pradesh Drug Controller Authority to cancel the manufacturing licence of Marion biotech after 22 out of 36 samples taken for testing from it were found adulterated with Ethylene glycol, said Gautam Budh Nagar Drug inspector on Saturday.

According to Gautam Budh Nagar Drug inspector, Uttar Pradesh, "Centre recommends the State Drug Controller Authority to cancel manufacturing licence of Marion biotech after 22 out of 36 samples taken for testing from it were found adulterated with Ethylene glycol."

On March 4, Uttar Pradesh Drugs Controlling and Licensing Authority recommended the Centre regarding cancellation of the license after the company has been found using substandard syrups. The company Marion Biotech had supplied the cough syrups that reportedly caused the deaths of Children in Uzbekistan.

The Marion Biotech Pvt Ltd had come under the scanner in December last year for its cough syrup Dok-1 which is suspected to have led to the death of 18 children who consumed it in Uzbekistan after which the CDSCO launched a probe into the matter.

Earlier on Friday, the Noida Police arrested three people for the manufacture and sale of duplicate medicines who are linked with the pharmaceutical firm that manufactured cough syrup whose use is alleged to have led to the death of some children in Uzbekistan last year. The accused have been identified as Atul Rawat, Tuhin Bhattacharya and Mool Singh and were arrested from Marion Biotech Pvt Ltd.

The case had been registered at Gautam Buddha Nagar Phase-3 Police Station under various sections of the Drugs and Cosmetics Act 1940. A probe had been launched last year into the Noida-based drug manufacturer after the deaths of 18 children in Uzbekistan. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Cough syrupMedicinesindian government

Next Story